Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis
NCT05633355Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of rocatinlimab in atopic dermatitis (AD), sponsored by Amgen. Started Jan 2023; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05633355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633355.